With the recent findings regarding the crucial roles of GSK3β and DYRK1A in diabetes pathogenesis, we believe that the development of potent and selective inhibitors for these targets could be of great importance to treat both T2D and AD. The gene discussed is GSK3B; the disease is type 2 diabetes mellitus.